Faruqi & Faruqi Investigation: Ocata Therapeutics, Inc.

Faruqi & Faruqi, LLP Announces the Investigation of Ocata Therapeutics, Inc. (OCAT) Over the Proposed Sale of the Company to Astellas Pharma Inc.


Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Ocata Therapeutics, Inc. (“Ocata” or the “Company”) (NasdaqGM: OCAT) for potential breaches of fiduciary duties in connection with the sale of the Company to Astellas Pharma Inc. for approximately $379 million.
The Company’s stockholders will only receive $8.50 per share in cash for each share of Company common stock they own. However the offer is below at least one analyst’s target price of $9.00 per share.
If you own common stock in Ocata and wish to obtain additional information and protect your investments free of charge, please fill out the form below or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Logo Twitter Facebook LinkedIn Google+